Wirestock
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients.
Enhertu was approved for the treatment of unresectable or metastatic HR-positive, HER2-low or HER2-ultra-low breast cancer, as determined by an
